We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
Recursion Pharmaceuticals (RXRX - Free Report) closed at $6.36 in the latest trading session, marking a +0.47% move from the prior day. This change outpaced the S&P 500's 0.22% gain on the day. Meanwhile, the Dow lost 0.33%, and the Nasdaq, a tech-heavy index, added 0.76%.
Coming into today, shares of the biotechnology company had lost 8.13% in the past month. In that same time, the Medical sector lost 3.79%, while the S&P 500 gained 1.47%.
The investment community will be closely monitoring the performance of Recursion Pharmaceuticals in its forthcoming earnings report. In that report, analysts expect Recursion Pharmaceuticals to post earnings of -$0.33 per share. This would mark year-over-year growth of 23.26%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $34.71 million, up 229.65% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$1.58 per share and revenue of $76.68 million, which would represent changes of 0% and +72.02%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Recursion Pharmaceuticals. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Currently, Recursion Pharmaceuticals is carrying a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. With its current Zacks Industry Rank of 73, this industry ranks in the top 29% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know
Recursion Pharmaceuticals (RXRX - Free Report) closed at $6.36 in the latest trading session, marking a +0.47% move from the prior day. This change outpaced the S&P 500's 0.22% gain on the day. Meanwhile, the Dow lost 0.33%, and the Nasdaq, a tech-heavy index, added 0.76%.
Coming into today, shares of the biotechnology company had lost 8.13% in the past month. In that same time, the Medical sector lost 3.79%, while the S&P 500 gained 1.47%.
The investment community will be closely monitoring the performance of Recursion Pharmaceuticals in its forthcoming earnings report. In that report, analysts expect Recursion Pharmaceuticals to post earnings of -$0.33 per share. This would mark year-over-year growth of 23.26%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $34.71 million, up 229.65% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$1.58 per share and revenue of $76.68 million, which would represent changes of 0% and +72.02%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Recursion Pharmaceuticals. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Currently, Recursion Pharmaceuticals is carrying a Zacks Rank of #3 (Hold).
The Medical - Drugs industry is part of the Medical sector. With its current Zacks Industry Rank of 73, this industry ranks in the top 29% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.